The Effect of the Addition of XXXX on Blood Pressure Control in African Americans Treated With a Thiazide-like Diuretic.

@entity1 @entity8 @entity101 @entity3624 @entity6662 @entity5052 @entity9804 @entity208 @entity4337 @entity414
UNASSIGNED: We tested the hypothesis that @entity3624 oxidase inhibition among African Americans receiving the @entity6662 -type diuretic @entity9804 may improve blood pressure control with fewer @entity5052 -related side effects. We performed a randomized, double-blind, placebo-controlled study of African Americans with Stage 1 @entity101 without clinically significant @entity8 . One hundred fifty African American @entity1 or @entity1 between the ages of 18 and 65  years who met the exclusion/inclusion criteria with untreated or treated @entity101 were started on @entity9804 (25  mg/d) and @entity4337 . After a 5-week run-in on @entity9804 , baseline testing was performed and they were randomized to @entity208 (300  mg/dL) or placebo with doses adjusted based on @entity414 levels and followed for 8  weeks. One hundred ten subjects completed the study. Baseline systolic blood pressures after the 5-week @entity9804 run-in were 119.9      13.6 in the @entity208 group and 117      11.2 in the placebo group indicating excellent blood pressure control with the single agent. After at least 4  week postrandomization, the difference in mean change in systolic blood pressure in @entity208 less placebo from visits 5 to 3 was 4.3  mm Hg (95% confidence interval, -0.2 to 8.7; P  =  .059). The difference in mean change in @entity414 levels over the same period was 2.1  mg/dL (95% confidence interval, 1.7-2.6; P  <  .001). The use of @entity9804 with or without @entity208 resulted in excellent blood pressure control. The addition of @entity208 tended to improve clinic blood pressure, but the difference from the group receiving @entity9804 alone was not statistically significant.
